| Literature DB >> 25529383 |
Madan H Jagasia1, Hildegard T Greinix2, Mukta Arora3, Kirsten M Williams4, Daniel Wolff5, Edward W Cowen6, Jeanne Palmer7, Daniel Weisdorf3, Nathaniel S Treister8, Guang-Shing Cheng9, Holly Kerr10, Pamela Stratton11, Rafael F Duarte12, George B McDonald9, Yoshihiro Inamoto13, Afonso Vigorito14, Sally Arai15, Manuel B Datiles16, David Jacobsohn17, Theo Heller18, Carrie L Kitko19, Sandra A Mitchell20, Paul J Martin9, Howard Shulman9, Roy S Wu21, Corey S Cutler22, Georgia B Vogelsang23, Stephanie J Lee9, Steven Z Pavletic6, Mary E D Flowers24.
Abstract
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD). The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence. Revisions have been made to address areas of controversy or confusion, such as the overlap chronic GVHD subcategory and the distinction between active disease and past tissue damage. Diagnostic criteria for involvement of mouth, eyes, genitalia, and lungs have been revised. Categories of chronic GVHD should be defined in ways that indicate prognosis, guide treatment, and define eligibility for clinical trials. Revisions have been made to focus attention on the causes of organ-specific abnormalities. Attribution of organ-specific abnormalities to chronic GVHD has been addressed. This paradigm shift provides greater specificity and more accurately measures the global burden of disease attributed to GVHD, and it will facilitate biomarker association studies.Entities:
Keywords: Chronic graft-versus-host disease; Diagnosis; National Institutes of Health; Staging
Mesh：
Substances：
Year: 2014 PMID： 25529383 PMCID： PMC4329079 DOI： 10.1016/j.bbmt.2014.12.001
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN： 1083-8791 Impact factor: 5.742